The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients

Diabetes, Obesity and Metabolism

Volumn 8, Issue 1, 2006, Pages 8-14

  Howes, Laurence Guy ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Fibrates; Lipoproteins; Statins; Type 2 diabetes; Vascular responsiveness

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARGININE; ASCORBIC ACID; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FENOFIBRATE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; SEROTONIN; SIMVASTATIN; TRIACYLGLYCEROL; UBIQUINONE;

BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEATH; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VASOCONSTRICTION; VASODILATATION;

EID: 33645964306     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00469.x     Document Type: Review

References (79)

1. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200-300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031-1037.
2. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
3. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
4. Byington RP, Furberg CD, Crouse JR III, Espeland MA, Bond MG. Pravastatin, lipids, atherosclerosis carotid arteries (PLAC-II). Am J Cardiol 1995; 76: 54C-59C.
5. Kjekshus J, Pedersen TR, Pyorala K, Olsson AG. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). J Am Coll Cardiol 1998; 81: 333-335.
6. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
7. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
8. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 2001; 285: 1585-1591.
9. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
10. Myers P, Wright T, Tanner M, Ostlund R. The effects of native LDL and oxidised LDL on EDRF bioactivity and nitric oxide production in vascular endothelium. J Lab Clin Med 1994; 124: 672-682.
11. Lewis TV, Dart AM, Chin-Dusting JP. Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovasc Res 1997; 34: 590-596.
12. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
13. Halcox JP, Nour KR, Zalos G et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1240.
14. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
15. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
16. Leung W, Lau C, Wong C. Beneficial effects of cholesterol lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 34: 1496-1500.
17. Eichstadt HW, Eskotter H, Hoffinarm I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-125A.
18. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
19. Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolaemic subjects. J Clin Invest 1990; 8: 228-234.
20. Stroes E, Koomans H, de Bruin T, Rabelink T. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
21. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-736.
22. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Throm Vasc Biol 2001; 21: 1712-1719.
23. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: Role of microdomains and oxidative stress. Circulation 2004; 109 (21 Suppl. 1): II34-II41.
24. Galle J, Bassenge E, Busse R. Oxidised low density lipoproteins potentiate vasoconstrictions to various contractile agonists by direct interaction with vascular smooth muscle. Circ Res 1990; 66: 1287-1293.
25. Galle J, Bassenge E. Effects of native and oxidised low-density lipoproteins on endothelium-independent vasomotion. Basic Res Cardiol 1991; 86 (Suppl. 2): 127-142.
26. Straznicky N, Howes LG, Lam W, Louis WJ. Pravastatin reduces cardiovascular reactivity to noradrenalin and angiotensin II in hypercholesterolaemic hypertensives. Am J Cardiol 1995; 75: 582-586.
27. Sung B, Izzo J, Orlowski W, Bateson M, Wilson M. HMG-CoA reductase inhibitor exaggerated blood pressure response to mental stress in normotensives with hypercholesterolaemia. Circulation 1994; 90 (Suppl. 2): 1565. [abstract]
28. Sung B, Ching M, Izzo J, Orlowski W, Bateson M, Wilson M. Hypercholesterolaemia impairs insulin-mediated but not nitroprusside-induced venodilation. Circulation 1995; 92 (Suppl. 1): 1154. [abstract]
29. Abbott D, Daher A, Manwaring P, Howes LG. Simvastatin reduces forearm vascular responsiveness to norepinephrine. Atherosclerosis 1997; 131: 263-264.
30. Andrews TC, Raby K, Barry J et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 9: 324-328.
31. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
32. McVeigh GE, Brennan GM, Johnston GD et al. Impaired endothelium-dependant and independent vasodilation in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
33. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
34. Williams SB, Cusco JA, Roddy M, Johnstone MT, Creager MA. Impaired nitric oxide mediated vasodilation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
35. Gazis A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (α-tocopherol) supplementation on vascular endothelial function in type 2 diabetes mellitus. Diabet Med 1999; 16: 304-311.
36. McVeigh GE, Brennan GM, Johnston GD et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1993; 36: 33-38.
37. Bohlen HG, Lash JM. Endothelium dependent vasodilation is preserved in non-insulin dependent zucker fatty diabetic rats. Am J Physiol 1995; 268: H2366-H2374.
38. Sakamoto S, Minami K, Niwa Y et al. Effect of exercise training and food restriction on endothelium dependent relaxation in the otsuka long-evans tokushima fatty rat, a model of spontaneous NIDDM. Diabetes 1998; 47: 82-86.
39. Wigg SJ, Tare M, Tonta M, O'Brien R, Meredith IT, Parkington HC. Comparison of the effects of diabetes mellitus on an EDHF-dependant and an EDHF-independent artery. Am J Physiol 2001; 281: H232-H240.
40. De Vriese AS, Verbeuren TJ, Van de Voorde JV, Lamiere NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Clin Pharmacol 2000; 130: 963-974.
41. Quilley J, Fulton D, McGiff JC. Hyperpolarizing factors. Biochem Pharmacol 1997; 54: 1059-1070.
42. Sandow SL. Factors, fiction and endothelium-derived hyperpolarizing factor. Clin Exp Pharmacol Physiol 2004; 31: 563-570.
43. Cooke JP, Oka RK. Atherogenesis and the arginine hypothesis. Curr Atheroscler Rep 2001; 3: 252-259.
44. Leiper J, Vallace P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-548.
45. Lin KY, Ito A, Asagami T et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992.
46. Katusic ZS. Vascular endothelial dysfunction: Does tetrahydrobiopterin play a role? Am J Physiol 2001; 281: H981-H986.
47. Alp NJ, Mussa S, Khoo J et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 2003; 112: 725-735.
48. Maejima K, Nakano S, Himeno M et al. Increased basal levels of plasma nitric oxide in type 2 diabetic subjects: Relationship to microvascular concentrations. J Diabetes Complications 2001; 15: 135-143.
49. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85: 929-932.
50. Tesfamariam B & Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 1992; 262: H1915-H1919.
51. Watts GF & Playford DA. Dyslipoproteinemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependant diabetes mellitus: A hypothesis. Atherosclerosis 1998; 141: 17-30.
52. Taylor PD, McCarthy AL, Thomas CR, Poston L. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br J Pharmacol 1992; 107: 393-399.
53. Makino Ohuchi K, Kamata K. Mechanisms underlying the attenuation of endothelium-dependent vasodilation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br J Pharmacol 2000; 130: 549-556.
54. Elliott TG, Cockcroft JR, Groop, Viberti GC, Ritter JM. Inhibition of nitric oxide synthase in forearm vasculature of insulin dependent diabetic patients: Blunted vasoconstriction in patients with microalbuminuria. Clin Sci 1993; 85: 687-693.
55. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium dependent and independent dilatation of forearm resistance arteries in men with diet-treated non insulin dependent diabetes: Role of dyslipidaemia. Clin Sci 1996; 91: 567-573.
56. Matsuda Y, Hirata K, Inoue N et al. High density lipoprotein reverses inhibitory effect of oxidised low density lipoprotein on endothelium dependent arterial relaxation. Circ Res 1993; 72: 1103-1109.
57. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelial dependant vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-568.
58. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002; 22: 799-804.
59. Mansourati J, Newman LG, Roman SH, Travis A, Rafey M, Phillips RA. Lipid lowering does not improve endothelial function in subjects with poorly controlled diabetes. Diabetes Care 2001; 24: 2152-2153.
60. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001; 52: 299-305.
61. Tran D, Lowy A, Howes JB, Howes LG. The effects of cervastatin on ambulatory blood pressure recordings and cardiovascular responsiveness is type 2 diabetic men. Diabetes Obes Metab (in press).
62. Capell WH, DeSouza CA, Poirier P et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23: 307-313.
63. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003; 168: 169-179.
64. Avogaro A, Miola M, Favaro A et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 2001; 31: 603-609.
65. Playford DA, Watts G, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 1254-1257.
66. Oparil S, Oberman A. Nontraditional cardiovascular risk factors. Am J Med Sci 1999; 317: 193-207.
67. Willich SN, Linderer T, Wegscheider K, Leizorovics A, Alamercery I, Schroder R. Increased morning incidence of myocardial infarction in the ISAM study: Absence with prior beta-adrenergic blockade. Circulation 1989; 80: 853-858.
68. Willich SN, Lewis M, Lowell H, Arntz H-R, Schubert F, Schroder R. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993; 329: 1684-1690.
69. Weidmann P, Beretta-Piccoli C, Trost BN. Pressor factors and responsiveness in hypertension accompanying diabetes mellitus. Hypertension 1985; 7 (6 Part II): II33-II42.
70. Trzeciak H, Boguslaw O, Kozlowski A, Chocilowska D, Bara A. Contractility of the tail artery in rats treated with bezafibrate and fed atherogenic diet. J Cardiovasc Pharmacol 1993; 22: 761-767.
71. Sposito AC, Mansur AP, Coelno OR, Nicolau JC, Damires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-1499.
72. Glorioso N, Troffa C, Filligheddu F et al. Effect of HMG-Ca reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-1286.
73. Ferrier KE, Muhlmann MH, Baguet JP et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-1025.
74. O'Callaghan CJ, Krum H, Conway EL et al. Short term effects of pravastatin on blood pressure in hypercholesterolemic hypertensive patients. Blood Press 1994; 3: 404-406.
75. Maramatsu J, Kobagashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with HMG Co-A reductase inhibitor pravastatin. Atherosclerosis 1997; 130: 179-182.
76. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
77. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: Insights into the relation between AII and cholesterol in atherogenesis. Am J Med Sci 2002; 323: 17-24.
78. Jonkers IJ, de Man FH, van der Laarse A et al. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens 2001; 19: 749-755.
79. Dodson PM. Hypertension and diabetes. Curr Med Res Opin 2002; 18 (Suppl. 1): S48-s57.